Figure 4
Principal component analysis (PCA) using the second derivative of the lipid region corresponding to control cells (black dots), HCV-replicating cells (red dots) and HCV-replicating cells treated with 2MAd (green dots), daclatasvir (orange dots), sofosbuvir (blue dots) and a combination of daclatasvir and sofosbuvir (pink dots) for seven days (b), 20 days (c) and loadings (a). |